Published in J Am Soc Hypertens on January 18, 2016
Physician-Pharmacist Collaborative Management: Narrowing the Socioeconomic Blood Pressure Gap. Hypertension (2016) 0.77
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care (1986) 22.65
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med (2009) 5.75
Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care (1999) 4.35
Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. Arch Intern Med (2011) 4.23
Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens (2005) 4.19
The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med (2009) 4.10
Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation (2011) 3.95
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol (2011) 3.08
Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation (2015) 3.03
Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens (2013) 2.69
Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension (2011) 2.51
A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Greenwich) (2008) 2.37
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus. Hypertension (2010) 2.02
Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol (2013) 1.97
Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension (2011) 1.95
2015 ACC Health Policy Statement on Cardiovascular Team-Based Care and the Role of Advanced Practice Providers. J Am Coll Cardiol (2015) 1.47
Evaluation of pharmacist care for hypertension in the Veterans Affairs patient-centered medical home: a retrospective case-control study. Am J Med (2014) 1.40
Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc (2013) 1.31
A cluster-randomized effectiveness trial of a physician-pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes (2010) 1.26
Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension (2014) 1.19
Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes (2015) 1.13
Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens (2014) 1.13
Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich) (2012) 1.10
Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med (2013) 1.00
Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study. J Am Heart Assoc (2014) 0.89
Pharmacist intervention for blood pressure control: medication intensification and adherence. J Am Soc Hypertens (2015) 0.89
Epidemiology, prognosis, and treatment of resistant hypertension. Pharmacotherapy (2013) 0.87
Using theory to predict implementation of a physician-pharmacist collaborative intervention within a practice-based research network. Res Social Adm Pharm (2013) 0.84
Physician Acceptance of a Physician-Pharmacist Collaborative Treatment Model for Hypertension Management in Primary Care. J Clin Hypertens (Greenwich) (2015) 0.83
Proceedings from Duke resistant hypertension think tank. Am Heart J (2014) 0.81
Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. J Hum Hypertens (2015) 0.80
Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. J Am Soc Hypertens (2015) 0.80
Blood pressure for optimal health-related quality of life in hypertensive patients. J Hypertens (2013) 0.77
Resistant Hypertension and Susceptible Outcomes: Exploring the Benefits of Aggressive Blood Pressure Control. J Clin Hypertens (Greenwich) (2015) 0.77
A mixed-method approach to evaluate a pharmacist intervention for veterans with hypertension. J Clin Hypertens (Greenwich) (2014) 0.77
Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease. Mov Disord (2015) 0.96
Pharmacist intervention for blood pressure control: medication intensification and adherence. J Am Soc Hypertens (2015) 0.89
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol (2016) 0.86